Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention.

Aged Aged, 80 and over Anticoagulants / therapeutic use Arterial Occlusive Diseases / epidemiology Female Follow-Up Studies Humans Incidence Italy / epidemiology Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications Male Middle Aged Platelet Aggregation Inhibitors / therapeutic use Protein Kinase Inhibitors / therapeutic use Recurrence Risk Factors Secondary Prevention / methods Time Factors Treatment Outcome

Chronic myeloid leukemia Recurrent arterial occlusive event Secondary prophylaxis

Journal

International journal of cardiology

ISSN: 1874-1754

Titre abrégé: Int J Cardiol

Pays: Netherlands

ID NLM: 8200291

Informations de publication

Date de publication:
01 08 2019

Historique:

received: 08 02 2019

revised: 03 04 2019

accepted: 16 04 2019

pubmed: 29 4 2019

medline: 24 3 2020

entrez: 29 4 2019

Statut: ppublish

Résumé

Risk of death is particularly high in patients with a previous history of arterial occlusive events (AOEs) and the probability for a recurrent event is around 20%. Little is known about recurrent AOE and the role of secondary prevention in patients with Chronic Myeloid Leukemia (CML) with previous AOE, treated with second- and third-generation tyrosine kinase inhibitors (2 We identified a real-life cohort of 57 consecutive adult CML patients treated with 2 The 60-month cumulative incidence rate of recurrent AOEs was 47.8 ± 10.9%. Despite a history of AOE, 10 patients (16%) were not receiving secondary preventative measures. Patients treated with nilotinib and ponatinib showed a higher incidence of recurrent AOEs (76.7 ± 14.3% and 64 ± 20.1%, respectively) than those treated with dasatinib and bosutinib (44 ± 24.2% and 30.5 ± 15.5%, respectively) (p = 0.01). Only treatment with a 2 CML patients with a previous history of AOE treated with 2

Sections du résumé

BACKGROUND

METHODS

We identified a real-life cohort of 57 consecutive adult CML patients treated with 2

RESULTS

The 60-month cumulative incidence rate of recurrent AOEs was 47.8 ± 10.9%. Despite a history of AOE, 10 patients (16%) were not receiving secondary preventative measures. Patients treated with nilotinib and ponatinib showed a higher incidence of recurrent AOEs (76.7 ± 14.3% and 64 ± 20.1%, respectively) than those treated with dasatinib and bosutinib (44 ± 24.2% and 30.5 ± 15.5%, respectively) (p = 0.01). Only treatment with a 2

CONCLUSION

CML patients with a previous history of AOE treated with 2

Identifiants

DOI: 10.1016/j.ijcard.2019.04.051 PMID: 31029498

pubmed: 31029498

pii: S0167-5273(19)30723-5

doi: 10.1016/j.ijcard.2019.04.051

pii:

doi:

Substances chimiques

Anticoagulants 0

Platelet Aggregation Inhibitors 0

Protein Kinase Inhibitors 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

124-127